S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
Trucker J.B. Hunt Has Left The Station
Albertsons Companies, Inc. Will Continue To Rally
Chipmaker SiTime Near All-Time High Ground On Strong Sales, Earnings Growth
Toyota to build $1.29B US battery plant employing 1,750
Want to Be a Super Saver? Here's What Super Savers Do and What We Can All Learn (no Matter Our Income Level) 
Commerce head out to save US jobs, 1 computer chip at a time
Facebook plans to hire 10,000 in Europe to build 'metaverse'
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
Trucker J.B. Hunt Has Left The Station
Albertsons Companies, Inc. Will Continue To Rally
Chipmaker SiTime Near All-Time High Ground On Strong Sales, Earnings Growth
Toyota to build $1.29B US battery plant employing 1,750
Want to Be a Super Saver? Here's What Super Savers Do and What We Can All Learn (no Matter Our Income Level) 
Commerce head out to save US jobs, 1 computer chip at a time
Facebook plans to hire 10,000 in Europe to build 'metaverse'
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
Trucker J.B. Hunt Has Left The Station
Albertsons Companies, Inc. Will Continue To Rally
Chipmaker SiTime Near All-Time High Ground On Strong Sales, Earnings Growth
Toyota to build $1.29B US battery plant employing 1,750
Want to Be a Super Saver? Here's What Super Savers Do and What We Can All Learn (no Matter Our Income Level) 
Commerce head out to save US jobs, 1 computer chip at a time
Facebook plans to hire 10,000 in Europe to build 'metaverse'
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
Trucker J.B. Hunt Has Left The Station
Albertsons Companies, Inc. Will Continue To Rally
Chipmaker SiTime Near All-Time High Ground On Strong Sales, Earnings Growth
Toyota to build $1.29B US battery plant employing 1,750
Want to Be a Super Saver? Here's What Super Savers Do and What We Can All Learn (no Matter Our Income Level) 
Commerce head out to save US jobs, 1 computer chip at a time
Facebook plans to hire 10,000 in Europe to build 'metaverse'
ASX:BGT

Bio-Gene Technology Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive BGT News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Gene Technology and its competitors with MarketBeat's FREE daily newsletter.


About Bio-Gene Technology

Bio-Gene Technology Limited, a biotechnology company, engages in developing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. It is involved in developing Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from the leaves of rare eucalyptus trees. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has collaborations with Pacific Discovery Services for studying Flavocide's mode of action; and the Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.

Headlines

With bumper harvests in two straight years, how are ASX agritech stocks performing?
June 8, 2021 |  msn.com
Bio-Gene Technology (ASX:BGT) Is In A Strong Position To Grow Its Business
May 24, 2021 |  finance.yahoo.com
ElevateBio raises $525 million to fuel growth in cell and gene therapy
March 15, 2021 |  msn.com
Cell and gene therapy startup raises $525M
March 15, 2021 |  bizjournals.com
Analysts Expect Breakeven For Bio-Gene Technology Limited (ASX:BGT) Before Long
February 23, 2021 |  finance.yahoo.com
Key Things To Understand About Bio-Gene Technology's (ASX:BGT) CEO Pay Cheque
November 25, 2020 |  finance.yahoo.com
Bio-Gene Technology Limited (BGT.AX)
October 29, 2020 |  finance.yahoo.com
Bio-Gene Technology Ltd.
October 14, 2020 |  wsj.com
Bug killer Bio-Gene is safe in water: study
June 4, 2020 |  www.msn.com
TechTalk: Agritech offers fertile upside for investors
June 2, 2020 |  www.msn.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
ASX
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
ASX:BGT
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.bio-gene.com.au
Phone
61 3 9628 4178
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$62,610.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
7.04
Book Value
A$0.03 per share
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
7.87
Quick Ratio
7.52

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
N/A
Market Cap
N/A
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Bio-Gene Technology (ASX:BGT) Frequently Asked Questions

What stocks does MarketBeat like better than Bio-Gene Technology?

Wall Street analysts have given Bio-Gene Technology a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bio-Gene Technology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Bio-Gene Technology's key executives?

Bio-Gene Technology's management team includes the following people:
  • Mr. Richard Jagger B.Sc., BSC (HONS), M.INTL.BUS, GAICD, MD, CEO & Director
  • Mr. Roger McPherson C.P.A., CPA, B.Bus, GAICD, CFO & Company Sec.
  • Mr. Peter Donald May AFAIM, M.B.A., MBA, AFA1M, GAICD, Exec. Director of R&D and Exec. Director

What is Bio-Gene Technology's stock symbol?

Bio-Gene Technology trades on the ASX under the ticker symbol "BGT."

How much money does Bio-Gene Technology make?

Bio-Gene Technology has a market capitalization of $0.00 and generates $62,610.00 in revenue each year.

What is Bio-Gene Technology's official website?

The official website for Bio-Gene Technology is www.bio-gene.com.au.

Where are Bio-Gene Technology's headquarters?

Bio-Gene Technology is headquartered at 100 Bellevue Pkwy, Wilmington, Delaware 19809-3700.

How can I contact Bio-Gene Technology?

Bio-Gene Technology's mailing address is 100 Bellevue Pkwy, Wilmington, Delaware 19809-3700. The company can be reached via phone at 61 3 9628 4178.


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.